|
WO2021050937A1
|
|
Methods for the treatment of arid1a-deficient cancers
|
|
WO2021050510A1
|
|
Engineered peptide and peptide mimetic compositions and methods
|
|
WO2021030450A1
|
|
Novel lox-1 antibody compositions, lox1 neutralization assay and methods of treatment using same
|
|
WO2021022107A1
|
|
Multivalent dna antibody constructs and use thereof
|
|
WO2021022113A1
|
|
Multivalent dna antibody constructs and use thereof
|
|
WO2021011876A2
|
|
Modulators of excitatory amino acid transporters and methods using same
|
|
WO2021003272A1
|
|
Use of lrp2 agonists for generating myeloid-derived suppressor cells
|
|
WO2020252195A1
|
|
Telomerase reverse transcriptase degraders and methods of use thereof
|
|
WO2020227605A2
|
|
Dna encoded il-36 gamma as an adjuvant
|
|
WO2020172510A1
|
|
Methods and compositions for treating cancer by targeting fatp2 and myeloid derived suppressor cells
|
|
WO2020160310A1
|
|
Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
|
|
WO2020146865A1
|
|
Dna monoclonal antibodies targeting pd-1 for the treatment and prevention of cancer
|
|
WO2020132699A1
|
|
Compositions comprising self-assembling vaccines and methods of using the same
|
|
WO2020132418A1
|
|
Vaccines against powassan virus, and methods of using same
|
|
WO2020092880A1
|
|
A novel dna vaccine against crimean-congo hemorrhagic fever virus (cchfv)
|
|
WO2020092662A1
|
|
Proteolysis-targeting chimeras
|
|
WO2020086939A1
|
|
Canine distemper vaccines and methods of treatment using the same
|
|
WO2020086782A1
|
|
Dna antibody constructs for use against hiv
|
|
WO2020081452A1
|
|
Compositions and methods for altering neutrophil migration and metastasis
|
|
WO2020072640A1
|
|
Compositions and methods for prevention and reduction of metastasis
|
